Journal Article DKFZ-2025-01784

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Repurposing Drug Metabolites into Dual β-Adrenergic Receptor-Carbonic Anhydrase Modulators as Potential Tools for Ocular Disorders.

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2025
ACS Washington, DC

Journal of medicinal chemistry nn, nn () [10.1021/acs.jmedchem.5c01459]
 GO

This record in other databases:

Please use a persistent id in citations: doi:

Abstract: We report the regioselective chemical derivatization of (R)-2-((4-aminophenethyl)amino)-1-phenylethan-1-ol, the primary metabolite of the β3-Adrenergic Receptor (β3-AR) agonist mirabegron, with prototypical Carbonic Anhydrase Inhibitors (CAIs) to afford the carbamates 10-14 and the ureido derivatives 15-18. Such compounds were endowed in vitro with distinct inhibition profiles for the human (h) Carbonic Anhydrases (CAs) and showed preferential agonisms for the β3-AR subtype. Among them, 14 induced remarkable intraocular pressure (IOP) lowering in an in vivo transient model of ocular hypertension, with the maximal effect at 120 min post-administration at 1% w/v concentration. Furthermore, the high stability of the compounds in rabbit plasma and their ability to induce full vasodilation in isolated porcine retinal arteries suggested that the observed in vivo effects likely result from a combination of conventional aqueous humor reduction and modulation of ocular vascular tone, both of which are mediated by CAs and β-ARs. The pronounced melanosomal accumulation of representative compounds 14 and 16 highlights their potential as ideal candidates for evaluating pharmacokinetic profiles in ophthalmic applications. The results of this study provide strong evidence for the biomedical repurposing of a neglected metabolite through a novel class of dual-targeting ligands, also offering a promising strategy to help counteract the ongoing decline in drug discovery.

Classification:

Note: epub

Contributing Institute(s):
  1. Immundiversität (D150)
Research Program(s):
  1. 314 - Immunologie und Krebs (POF4-314) (POF4-314)

Appears in the scientific report 2025
Database coverage:
Medline ; BIOSIS Previews ; Biological Abstracts ; Chemical Reactions ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; Ebsco Academic Search ; Essential Science Indicators ; Index Chemicus ; NationallizenzNationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Public records
Publications database

 Record created 2025-08-27, last modified 2025-08-28



Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)